1404 related articles for article (PubMed ID: 19770659)
1. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
Csernok E; Lamprecht P; Gross WL
Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of PR3-ANCA associated vasculitis.
Kallenberg CG
J Autoimmun; 2008; 30(1-2):29-36. PubMed ID: 18162369
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of ANCA-associated vasculitides.
Kallenberg CG
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i59-63. PubMed ID: 21339221
[TBL] [Abstract][Full Text] [Related]
4. IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients.
Harper L; Radford D; Plant T; Drayson M; Adu D; Savage CO
Arthritis Rheum; 2001 Apr; 44(4):921-30. PubMed ID: 11315931
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
Almroth G; Berlin G; Andersson B; Hahn-Zoric M
Scand J Urol Nephrol; 2009; 43(2):160-70. PubMed ID: 18979374
[TBL] [Abstract][Full Text] [Related]
6. [Antineutrophilic cytoplasmic antibodies (ANCA) in inflammatory rheumatic diseases: immunodiagnostic and immunopathogenetic aspects].
Csernok E; Gross WL
Z Rheumatol; 1995; 54(1):26-38. PubMed ID: 7725808
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides.
Kallenberg CG; Heeringa P; Stegeman CA
Nat Clin Pract Rheumatol; 2006 Dec; 2(12):661-70. PubMed ID: 17133251
[TBL] [Abstract][Full Text] [Related]
8. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
Ozaki S
Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
[TBL] [Abstract][Full Text] [Related]
9. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis.
Gross WL; Csernok E
Curr Opin Rheumatol; 1995 Jan; 7(1):11-9. PubMed ID: 7718417
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies.
Choi HK; Liu S; Merkel PA; Colditz GA; Niles JL
J Rheumatol; 2001 Jul; 28(7):1584-90. PubMed ID: 11469466
[TBL] [Abstract][Full Text] [Related]
11. Epitope-specific anti-neutrophil cytoplasmic antibodies: do they matter? Can they be detected?
Specks U
APMIS Suppl; 2009 Jun; (127):63-6. PubMed ID: 19515143
[TBL] [Abstract][Full Text] [Related]
12. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?
Millet A; Pederzoli-Ribeil M; Guillevin L; Witko-Sarsat V; Mouthon L
Ann Rheum Dis; 2013 Aug; 72(8):1273-9. PubMed ID: 23606701
[TBL] [Abstract][Full Text] [Related]
13. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis.
Reynolds WF; Stegeman CA; Tervaert JW
Clin Immunol; 2002 May; 103(2):154-60. PubMed ID: 12027420
[TBL] [Abstract][Full Text] [Related]
14. [Antineutrophil cytoplasmic antibody(ANCA)].
Yoshida M
Rinsho Byori; 2003 Jul; 51(7):644-8. PubMed ID: 12924248
[TBL] [Abstract][Full Text] [Related]
15. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase.
Popa ER; Franssen CF; Limburg PC; Huitema MG; Kallenberg CG; Tervaert JW
Arthritis Rheum; 2002 Jul; 46(7):1894-904. PubMed ID: 12124874
[TBL] [Abstract][Full Text] [Related]
16. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing.
Rao DA; Wei K; Merola JF; O'Brien WR; Takvorian SU; Dellaripa PF; Schur PH
J Rheumatol; 2015 May; 42(5):847-52. PubMed ID: 25834211
[TBL] [Abstract][Full Text] [Related]
17. Antineutrophil cytoplasmic autoantibody testing in vasculitides.
Gross WL
Rheum Dis Clin North Am; 1995 Nov; 21(4):987-1011. PubMed ID: 8592745
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions.
Peikert T; Finkielman JD; Hummel AM; McKenney ME; Gregorini G; Trimarchi M; Specks U
Arthritis Rheum; 2008 May; 58(5):1546-51. PubMed ID: 18438818
[TBL] [Abstract][Full Text] [Related]
19. [Review article: Antineutrophil cytoplasmic antibody in small vessel vasculitis].
Nakano H; Ozaki S
Rinsho Byori; 2010 May; 58(5):480-9. PubMed ID: 20560457
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
Kim SM; Choi SY; Kim SY; Kim J
Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
